
Bemesetron
CAS No. 40796-97-2
Bemesetron( MDL 72222 | 3-TROPANYL-3,5-DICHLOROBENZOATE | TROPANYL 3,5-DICHLOROBENZOATE )
Catalog No. M26626 CAS No. 40796-97-2
Bemesetron is a selective antagonist of 5-HT3 (IC50 = 0.33 nM) with neuroprotective effects.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 45 | In Stock |
![]() ![]() |
25MG | 58 | In Stock |
![]() ![]() |
50MG | 77 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameBemesetron
-
NoteResearch use only, not for human use.
-
Brief DescriptionBemesetron is a selective antagonist of 5-HT3 (IC50 = 0.33 nM) with neuroprotective effects.
-
DescriptionBemesetron is a selective antagonist of 5-HT3 (IC50 = 0.33 nM) with neuroprotective effects.(In Vitro):In primary cortical neuronal cells, Bemesetron (1 μM) significantly blocks the H2O2-induced increase of caspase-3 immunoreactivity. Bemesetron (0.01, 0.1 and 1 μM) and Y25130 (0.05, 0.5 and 5 μM) concentration-dependently reduce the H2O2-induced decrease showing inhibition of 74.9 and 79.0% with 1 μM and 5 μM, respectively.(In Vivo):In male adult albino mice, Bemesetron (1 mg/kg; i.p.) causes a significant reduction of catalepsy, while Bemesetron (10 mg/kg; i.p.) significantly potentiates the phenomenon. The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol.
-
In VitroBlockade of 5-HT3 receptor with Bemesetron (MDL7222) reduces hydrogen peroxide-induced neurotoxicity in cultured rat cortical cells. Bemesetron (0.01, 0.1 and 1 μM, 15 hours) and Y25130 (0.05, 0.5 and 5 μM) concentration-dependently reduce the H2O2-induced decrease of MTT reduction showing 74.9±2.4 and 79.0 ±2.5% with 1 μM and 5 μM, respectively, which are maximal effects. Pretreatment (20 minutes) with Bemesetron (1 μM), Y25130 (5 μM) or MK-801 (10 μM) significantly, but not completely, inhibits the H2O2-induced elevation of [Ca2+]c. Bemesetron (1 μM, 15 hours) significantly blocks the H2O2-induced increase of caspase-3 immunoreactivity.Cell Viability Assay Cell Line:Primary cortical neuronal cells Concentration:0.01-1 μM Incubation Time:20 minutes (pretreatment); 15 hours (post-incubation)Result:Concentration-dependently reduced the H2O2-induced decrease of MTT reduction showing 74.9±2.4% with 1 μM, which was maximal effect.Western Blot Analysis Cell Line:Primary cortical neuronal cells Concentration:1 μM Incubation Time:15 hours Result:Blocked significantly the H2O2-induced increase of caspase-3 immunoreactivity.
-
In VivoBemesetron (0.1, 1 and 10 mg/kg; i.p.) is used in male adult albino mice. The lowest dose do not cause any significant change in catalepsy. However, Bemesetron (1 mg/kg) causes a significant reduction of catalepsy (from 90 min after Haloperidol), while 10 mg/kg significantly potentiates the phenomenon (from 60 min after Haloperidol). The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol. Animal Model:Male adult albino mice, weighing 26-36 g Dosage:0.1-10 mg/kg Administration:Intraperitoneally injected, 20 min (pretreatment) +180 min (treatment)Result:Reduced catalepsy significantly at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect.
-
SynonymsMDL 72222 | 3-TROPANYL-3,5-DICHLOROBENZOATE | TROPANYL 3,5-DICHLOROBENZOATE
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
RecptorNLRP3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number40796-97-2
-
Formula Weight314.21
-
Molecular FormulaC15H17Cl2NO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (6.37 mM)
-
SMILESCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ruan S, et al. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3. Int Immunopharmacol. 2021 Nov;100:108126.
molnova catalog



related products
-
Quetiapin
Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder.
-
Peptide 401
Peptide 401 is an antimicrobial peptide (AMP) derived from the venom of bees and wasps. Peptide 401 induces mast cell degranulation, activating histamine release from peritoneal mast cells. Additionally, peptide 401 exhibits some anti-inflammatory activity, decreasing paw edema in animal models.
-
Vortioxetine (Lu AA2...
Vortioxetine (Lu AA21004) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT.